Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 3Docetaxel 3belinostat 2Fluorouracil 2Filgrastim 2venetoclax 1toripalimab 1spartalizumab 1resiquimod 1poly ICLC 1ivosidenib 1enasidenib 1durvalumab 1birinapant 1alanosine 1Topotecan 1Thiotepa 1Thalidomide 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Metformin 1Medicare Part B 1Leucovorin 1Irinotecan 1Ipilimumab 1Immunotherapy 1IFL protocol 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × Medicare Part B × Gastrointestinal × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡